|
EPM2AIP1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.08550000099683E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
5.42889999621821E-08 |
| Normal-vs-Stage2 |
2.366200E-04 |
| Normal-vs-Stage3 |
2.41839881454098E-11 |
| Normal-vs-Stage4 |
1.56560000519335E-08 |
| Stage1-vs-Stage2 |
4.339400E-01 |
| Stage1-vs-Stage3 |
4.434000E-02 |
| Stage1-vs-Stage4 |
4.805600E-02 |
| Stage2-vs-Stage3 |
4.791900E-02 |
| Stage2-vs-Stage4 |
5.613800E-02 |
| Stage3-vs-Stage4 |
6.898400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.68289998498028E-09 |
| Normal-vs-AfricanAmerican |
3.681200E-03 |
| Normal-vs-Asian |
1.51690000005367E-07 |
| Caucasian-vs-AfricanAmerican |
3.746400E-01 |
| Caucasian-vs-Asian |
7.631200E-01 |
| AfricanAmerican-vs-Asian |
4.924000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.22179999451077E-08 |
| Normal-vs-Female |
8.23040002817521E-09 |
| Male-vs-Female |
5.268600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
5.21380000284566E-08 |
| Normal-vs-Age(41-60Yrs) |
2.34369967877512E-10 |
| Normal-vs-Age(61-80Yrs) |
6.83760004172029E-09 |
| Normal-vs-Age(81-100Yrs) |
1.800400E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.047200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.328600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.173600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.754800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.381600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.111200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.23499999999488E-05 |
| Classical-VS-Follicular |
1.009850E-02 |
| Classical-VS-Other |
5.434400E-01 |
| Classical-VS-Normal |
6.8376999950992E-08 |
| Tall-VS-Follicular |
1.6289000004388E-07 |
| Tall-VS-Other |
7.443700E-03 |
| Tall-VS-Normal |
4.10282918750227E-12 |
| Follicular-VS-Other |
8.115000E-01 |
| Follicular-VS-Normal |
2.216000E-04 |
| Other-VS-Normal |
6.895800E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.05799996436207E-09 |
| Normal-vs-N1 |
2.29720000022304E-07 |
| N0-vs-N1 |
4.532600E-01 |
|
|
